Fosfomycin does not inhibit the tumoricidal efficacy of cisplatinum

Laryngoscope

Volumn 109, Issue 8, 1999, Pages 1259-1262

  Jordan, Jennifer A ^a   Schwade, Nathan D ^a   Truelson, John M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cisplatinum; Fosfomycin; Squamous cell carcinoma

Indexed keywords

CISPLATIN; FOSFOMYCIN;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEPHROTOXICITY; NONHUMAN; NUDE MOUSE; OTOTOXICITY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTI-BACTERIAL AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FOSFOMYCIN; HEARING LOSS, SENSORINEURAL; KIDNEY DISEASES; MICE; MICE, INBRED BALB C; MICE, NUDE; PROSPECTIVE STUDIES; TUMOR CELLS, CULTURED;

EID: 0032769076     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-199908000-00014     Document Type: Article

References (17)

1. VonRoemeling R, Hrushecky WJ. Principles of chemotherapy and immunotherapy for head and neck cancer. In: Paparella MM, Shumrick DA, Gluckman JL, Meyerhoff WL, eds. Otolaryngology. Philadelphia: WB Saunders; 1991: 617-639.
2. Komura S, Asakuma S, Snow JB Jr. Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum. Otolaryngol Head Neck Surg 1981;89:275-282.
3. Saferstein RL. Cisplatinum nephrotoxicity. Am J Kidney Dis 1986;8:356-367.
4. Schaefer S, Post JD, Close LG, Wright CG. Ototoxicity of low and moderate dose cis-platinum. Cancer 1985;56: 1934-1939.
5. Thompson SW, Davis LE, Kornfeld M, Hilges RD, Standeler JC. Cisplatin neuropathy: clinical, electrophysiological, morphologic, and toxicologic studies. Cancer 1984;56: 1269-1271.
6. Choie DD, Longnecker DS, Delcampo AA. Acute and chronic cisplatin nephrotoxicity in rats. Lab Invest 1981;44: 397-402.
7. Schweitzer VG, Dolan DF, Davidson T, Abrams GE, Snyder R. Amelioration of cis-platin-induced ototoxicity by fosfomycin. Laryngoscope 1986;96:948-958.
8. Ohtani I. Reduction of cisplatinum toxicity by fosfomycin in animal models. Jpn J Cancer Chemother 1984;11: 2400-2407.
9. Ohtani I. Protective effect of fosfomycin against cisplatin induced ototoxicity in rats. Ear Res Jpn 1985;15:290-292.
10. Schweitzer VG. Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope 1993; 103:1-52.
11. Umeki S. Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity. Am J Med Sci 1988; 295:6-10.
12. Hayashi M, Numaguchi M, Watabe H, Enomoto H, Yaoi, Y. Cisplatin-induced nephrotoxicity, the protective effect of fosfomycin on it as demonstrated by using a crossover study of urinary metabolite levels. Acta Obstet Gynecol Scand 1997;76:590-595.
13. Olsen J, Truelson J, Street N. In vitro interaction of cisplatin and fosfomycin on squamous cell carcinoma cultures. Arch Otolaryngol 1994;120:1253-1257.
14. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J Immunol Methods 1983;65:55-63.
15. Kaltenbach JA, Church MW, Blakley BW, McCaslin DL, Burgio DL. Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster. Otolaryngol Head Neck Surg 1997;117:493-500.
16. Wagner T, Kreft B, Bohlmann G, Schwieder G. Effects of fosfomycin, mesna, and sodium thiosulfate on the toxicity and antitumor activity of cisplatin. J Cancer Res Clin Oncol 1988;114:497-501.
17. Ohtsuki K. Protective effect of fosfomycin against aminoglycoside induced ototoxicity. Nippon Jibiinkoka Gakkai Kaiho 1983;86:1487-1496.